News

  • 2017 Liver Meeting Highlights

    October 27, 2017

    Attending the Liver Meeting 2017, the American Association for the Study of Liver Diseases (AASLD)‘s 68th annual meeting, this year were not only researchers and physicians, but also a number of different blog writers. The below are links to some abstracts and blog posts about information presented at this year’s Liver Meeting. A Few 2017 Liver ...

  • Gilead Receives Health Canada Approval for VOSEVI™, the First Once-Daily, Single Tablet HCV Regimen for Re-Treatment

    August 17, 2017

    Please note:  VOSEVI is available to eligible patients in Canada but is not yet covered by BC PharmaCare (or any provincial plans).  VOSEVI is included in Gilead’s Momentum Patient Support Program (information, including contact information, is available below and here). See the Hep C Treatment Diagram on the left hand side of this page (homepage has ...

  • AbbVie’s MAVIRET™ Approved by Health Canada for the Treatment of Chronic Hepatitis C in All Major Genotypes

    August 17, 2017

    Please note:  MAVIRET is available to eligible patients in Canada but is not yet covered by BC PharmaCare (or any provincial plans).  MAVIRET is included in AbbVie’s patient support program, AbbVie Care. Information, including contact information, is available here and here. See the Hep C Treatment Diagram on the left hand side of this page (homepage ...

  • National screening guidelines for hep C abandon baby boomers.

    April 26, 2017

    Once again, the largest group of people at risk for living with hepatitis C in Canada  – baby boomers – are excluded from the Canadian Task Force on Preventive Health (CTFPH)’s hepatitis C screening guideline recommendations. As a community-based, lived experience organization, we urge testing of all at-risk groups, including those born between 1945 – 1965 ...

  • Candidate Questionnaire – 2017 Provincial Election

    April 18, 2017

    All candidates running for office in this 2017 provincial election have been sent this questionnaire and background information.  Results from candidates and parties will be posted in blogs leading up to the election.   Our question:  Do you support PHCN’s 5 Point Plan to help eliminate hepatitis C from BC by 2030? Feel free to check ...

  • The PHCN’s News in Review Newsletter (06/04/17)

    April 6, 2017

    Welcome to the Pacific Hepatitis C Network (PHCN)‘s Hepatitis C News in Review Newsletter. This is where we review all of the major current issues and events around hepatitis C and hep C treatments. It is an email that includes links to our recent blog posts—including links to a blog post about the importance of ...

  • Hepatitis C Elimination is Possible and Essential

    April 6, 2017

    Twelve years ago a neonatal nurse adopted Kagen, a blonde haired blue-eyed baby boy. He’s now tall, sports a buzz cut, and likes playing Pokemon Go and visiting Build-A-Bear. With the desire to help people in rural Appalachia, Naomi became a registered nurse and had dreams of one day becoming a doctor. While working in the ...

  • Relapse, Recurrence, Null & Partial Response/rs: The Basics

    April 4, 2017

    In hepatitis C and hep C treatment there are three ‘R’s that are big, sad, and scary. They are the bringers of sadness that if doctors, friends, and communities could protect someone from, they would. The Three ‘R’s of Hepatitis C Treatment Recurrence When treatment has been successful but over time the person has been infected with the ...

  • Epclusa, Zepatier, Daklinza, and Sunvepra Expanded Coverage

    April 4, 2017

    Coverage for four hepatitis C treatments is changing. The four new hepatitis C treatments (Epclusa, Zepatier, Daklinza, and Sunvepra) are being added to provincial formularies across Canada. Treatment Coverage Across Canada Treatment coverage across Canada is decided upon by each province and territory. This means that not only can treatments vary, and be compared to each other, ...

  • Technivie and BC PharmaCare

    April 1, 2017

    Technivie, the hepatitis C treatment, was approved for use in Canada in October 2015 and then later went on to pursue approval for BC PharmaCare coverage in January 2016. However, negotiations that may have led to BC PharmaCare coverage being granted in the near future were closed as an agreement couldn’t be reached between AbbVie and ...